Stocks to Watch
Sempra outbids Buffett for Oncor, Fiat Chrysler soars on takeover talk, Nike gets downgraded
| Previous Close | 114.2800 |
| Open | 114.2500 |
| Bid | 114.2500 x 400 |
| Ask | 114.2600 x 2600 |
| Day's Range | 114.0100 - 114.3600 |
| 52 Week Range | 102.0700 - 121.2400 |
| Volume | 238,039 |
| Avg. Volume | 2,081,149 |
| Net Assets | 36.9B |
| NAV | 117.20 |
| PE Ratio (TTM) | -59.46 |
| Yield | 2.21% |
| YTD Return | 5.80% |
| Beta (3y) | 0.98 |
| Expense Ratio (net) | 0.20% |
| Inception Date | 2000-05-22 |
- Market Realist•27 minutes ago
Orencia Could Witness Robust Growth in 2017
In 2Q17, Orencia contributed around 13% of Bristol-Myers Squibb’s net revenues.
- Market Realist•5 days ago
Dentsply Sirona’s Technologies Segment Sales Declined in 2Q17
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
- Market Realist•6 days ago
What Kyprolis Could Do for Amgen’s Revenue Growth
In 2Q17, Amgen’s (AMGN) Kyprolis generated revenues of ~$211 million, which reflected ~23% growth on a YoY (year-over-year) basis and ~11% growth QoQ (quarter-over-quarter). In 2Q17, Kyprolis witnessed ...
